logo
Twitter
Discord
Email
logo
Vaxcyte, Inc.

Vaxcyte, Inc.

NASDAQ•PCVX
CEO: Mr. Grant E. Pickering M.B.A.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2020-06-12
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Contact Information
825 Industrial Road, Suite 300, San Carlos, CA, 94070, United States
650-837-0111
vaxcyte.com
Market Cap
$5.46B
P/E (TTM)
-8.6
45.8
Dividend Yield
--
52W High
$107.31
52W Low
$27.66
52W Range
18%
1.6
F-Score
Modified Piotroski Analysis
Based on 8-year fundamentals
Weak • 1.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2017-2024

Financial Dashboard

Q3 2025 Data

Revenue

$0.00+0.00%
4-Quarter Trend

EPS

-$1.56+87.95%
4-Quarter Trend

FCF

-$147.13M+48.93%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

VAX-31 Advances to Phase 3 Selected VAX-31 High dose for adult Phase 3 pivotal study starting December 2025; topline data anticipated in 2026.
VAX-24 Infant Data Positive Final safety and immunogenicity results from VAX-24 infant Phase 2 study showed robust, dose-dependent immune responses.
Commercial Manufacturing Secured Agreement established with Thermo Fisher for long-term U.S. commercial supply commitment reaching up to $1.0B.
Significant Net Loss Widens Nine months net loss reached $520.1M USD, a 59.1% increase from $326.8M USD in prior period.

Risk Factors

Highly Speculative Investment Company remains in clinical stages with no product revenue; incurred $1.91B accumulated deficit to date.
Substantial Future Funding Required Operations require substantial additional capital; existing cash reserves estimated to fund plans for at least 12 months.
Pipeline Development Uncertainty Vaccine candidates may fail in development or face material delays, severely harming commercial viability and prospects.
Third-Party Manufacturing Reliance Business depends on third-party CMOs for supply; interruptions or failure to meet cGMP standards adversely affect operations.

Outlook

VAX-31 Phase 3 Execution Plan to initiate pivotal VAX-31 adult Phase 3 study in December 2025, with remaining Phase 3 studies planned for 2026.
Pipeline Prioritization Continues Strategic focus remains on PCV franchise advancement; VAX-A1 and VAX-GI programs are currently paused.
Managing Cash Runway Expect expenses to increase as clinical trials advance; cash position must support operations through at least 12 months.
Expanding Commercial Readiness Appointed new Chief Commercial Officer to lead global commercialization strategy, preparing for potential future product launches.

Peer Comparison

Revenue (TTM)

PTC Therapeutics, Inc.PTCT
$1.78B
+97.5%
Alkermes plcALKS
$1.52B
+1.1%
Arrowhead Pharmaceuticals, Inc.ARWR
$596.57M
+2936.3%

Gross Margin (Latest Quarter)

Axsome Therapeutics, Inc.AXSM
93.0%
+1.1 pp
PTC Therapeutics, Inc.PTCT
92.5%
-2.0 pp
Alkermes plcALKS
86.9%
+3.6 pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
RNA$8.98B-19.8-33.5%0.4%
AXSM$7.03B-30.4-357.2%32.3%
NUVL$6.97B-18.1-39.5%0.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 4, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-1.56+88.0%
    N/A

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 6, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-1.22+11.3%
    N/A

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 7, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-1.04+22.4%
    N/A

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 25, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-3.80+8.2%
    N/A

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 5, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.83-8.8%
    N/A

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 6, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-1.10+57.1%
    N/A

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 8, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.85+51.8%
    N/A

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 27, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-4.14-12.2%
    N/A